- Home
- MIRM vs NSIT Comparison
MIRM vs NSIT Comparison
Compare MIRM & NSIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- NSIT
- Stock Information
- Founded
- MIRM 2018
- NSIT 1988
- Country
- MIRM United States
- NSIT United States
- Employees
- MIRM N/A
- NSIT N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- NSIT EDP Services
- Sector
- MIRM Health Care
- NSIT Technology
- Exchange
- MIRM Nasdaq
- NSIT Nasdaq
- Market Cap
- MIRM 3.8B
- NSIT 3.4B
- IPO Year
- MIRM 2019
- NSIT 1995
- Fundamental
- Price
- MIRM $72.65
- NSIT $100.00
- Analyst Decision
- MIRM Strong Buy
- NSIT Buy
- Analyst Count
- MIRM 11
- NSIT 3
- Target Price
- MIRM $79.00
- NSIT $168.33
- AVG Volume (30 Days)
- MIRM 560.3K
- NSIT 418.0K
- Earning Date
- MIRM 11-04-2025
- NSIT 10-30-2025
- Dividend Yield
- MIRM N/A
- NSIT N/A
- EPS Growth
- MIRM N/A
- NSIT N/A
- EPS
- MIRM N/A
- NSIT 4.21
- Revenue
- MIRM $429,161,000.00
- NSIT $8,271,548,000.00
- Revenue This Year
- MIRM $53.14
- NSIT $0.41
- Revenue Next Year
- MIRM $19.83
- NSIT $4.96
- P/E Ratio
- MIRM N/A
- NSIT $23.74
- Revenue Growth
- MIRM 62.33
- NSIT N/A
- 52 Week Low
- MIRM $36.88
- NSIT $97.30
- 52 Week High
- MIRM $78.55
- NSIT $195.53
- Technical
- Relative Strength Index (RSI)
- MIRM 52.77
- NSIT 23.59
- Support Level
- MIRM $68.34
- NSIT $97.30
- Resistance Level
- MIRM $71.96
- NSIT $111.54
- Average True Range (ATR)
- MIRM 2.53
- NSIT 3.07
- MACD
- MIRM -0.13
- NSIT -0.35
- Stochastic Oscillator
- MIRM 56.54
- NSIT 18.99
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.